Mortality in patients with septic shock correlates with anti-inflammatory but not proinflammatory immunomodulatory molecules

Journal of Intensive Care Medicine

Volumn 26, Issue 2, 2011, Pages 125-132

  De Pablo, Raúl ^a,b   Monserrat, Jorge ^b   Reyes, Eduardo ^b   Diaz Martin, David ^b   Rodriguez Zapata, Manuel ^b   Carballo, Fernando ^c   De La Hera, Antonio ^b   Prieto, Alfredo ^b   Alvarez Mon, Melchor ^a,b  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

cytokines; inflammatory response; multiple organ dysfunction syndrome; outcome; sepsis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL ADMISSION; HUMAN; IMMUNOMODULATION; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEPTIC SHOCK; SURVIVAL;

AGED; FEMALE; HUMANS; INTENSIVE CARE; INTERFERON-GAMMA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; ROC CURVE; SENSITIVITY AND SPECIFICITY; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953897079     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066610384465     Document Type: Article

References (36)

1. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138-150. (Pubitemid 36056721)
2. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644-1655.
3. Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anaesth. 1996;77(1):110-117.
4. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117(4):1162-1172. (Pubitemid 30228378)
5. From the bench to the bedside: the future of sepsis research. Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop. Chest. 1997;111(3):744-753.
6. Eichacker PQ, Parent C, Kalil A, et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med. 2002;166(9):1197-1205. (Pubitemid 35222596)
7. Deitch EA. Tumor necrosis factor as the proximal mediator of sepsis-or this too will pass. Crit Care Med. 1995;23(9):1457-1458.
8. Ashare A, Powers LS, Butler NS, Doerschug KC, Monick MM, Hunninghake GW. Anti-inflammatory response is associated with mortality and severity of infection in sepsis. Am J Physiol Lung Cell Mol Physiol. 2005;288(4):L633-L640. (Pubitemid 40404130)
9. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992;89(11):4845-4849.
10. Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock. 1998;9(1):1-11. (Pubitemid 128463868)
11. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res. 1990;49(2):186-196. (Pubitemid 20241651)
12. O'Reilly M, Newcomb DE, Remick D. Endotoxin, sepsis, and the primrose path. Shock. 1999;12(6):411-420.
13. Kox WJ, Volk T, Kox SN, Volk HD. Immunomodulatory therapies in sepsis. Intensive Care Med. 2000;26(suppl 1):S124-S128. (Pubitemid 30184503)
14. Mannick JA, Rodrick ML, Lederer JA. The immunologic response to injury. J Am Coll Surg. 2001;193(3):237-244. (Pubitemid 32834762)
15. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology. 2005;115(1):1-20. (Pubitemid 40598088)
16. Cavaillon JM, Adib-Conquy M, Fitting C, Adrie C, Payen D. Cytokine cascade in sepsis. Scand J Infect Dis. 2003;35(9):535-544. (Pubitemid 37336870)
17. Calandra T, Baumgartner JD, Grau GE, et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis. 1990;161(5):982-987. (Pubitemid 20148336)
18. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993;119(8):771-778. (Pubitemid 24012641)
19. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med. 1989;17(10):975-978. (Pubitemid 19252957)
20. Endo S, Inada K, Inoue Y, et al. Two types of septic shock classified by the plasma levels of cytokines and endotoxin. Circ Shock. 1992;38(4):264-274.
21. Offner F, Philippe J, Vogelaers D, et al. Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med. 1990;116(1):100-105. (Pubitemid 20250753)
22. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2004;(1):CD003574.
23. Taylor PC. Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. Mol Biotechnol. 2001;19(2):153-168. (Pubitemid 32999908)
24. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996;334(26):1697-1702. (Pubitemid 26193621)
25. Vincent JL, Abraham E. The last 100 years of sepsis. Am J Respir Crit Care Med. 2006;173(3):256-263. (Pubitemid 43209078)
26. Calvano SE, van der PT, Coyle SM, Barie PS, Moldawer LL, Lowry SF. Monocyte tumor necrosis factor receptor levels as a predictor of risk in human sepsis. Arch Surg. 1996;131(4):434-437. (Pubitemid 26113435)
27. Ertel W, Scholl FA, Gallati H, Bonaccio M, Schildberg FW, Trentz O. Increased release of soluble tumor necrosis factor receptors into blood during clinical sepsis. Arch Surg. 1994;129(12):1330-1336.
28. Goldie AS, Fearon KC, Ross JA, et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA. 1995;274(2):172-177.
29. Rogy MA, Coyle SM, Oldenburg HS, et al. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg. 1994;178(2):132-138. (Pubitemid 24073489)
30. Schroder J, Stuber F, Gallati H, Schade FU, Kremer B. Pattern of soluble TNF receptors I and II in sepsis. Infection. 1995;23(3):143-148.
31. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest. 1993;103(2):565-575.
32. Rigato O, Salomao R. Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis. Shock. 2003;19(2):113-116.
33. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997;3(6):678-681. (Pubitemid 27264980)
34. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol. 2002;168(11):5817-5823. (Pubitemid 34556169)
35. Iglesias J, Marik PE, Levine JS. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock. Am J Kidney Dis. 2003;41(1):62-75. (Pubitemid 36043352)
36. Osuchowski MF, Welch K, Yang H, Siddiqui J, Remick DG. Chronic sepsis mortality characterized by an individualized inflammatory response. J Immunol. 2007;179(1):623-630. (Pubitemid 46986580)